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ABSTRACT
Ovarian cancer constitutes one of the most lethal gynaecological malignancies 
worldwide and currently no satisfactory therapeutic approaches have been 
established. Therefore, elucidation of molecular mechanisms to develop targeted 
therapy of ovarian cancer is crucial. PDLIM2 is critical to promote ubiquitination 
of nuclear p65 and thus its role in inflammation has been highlighted recently. We 
demonstrate that PDLIM2 is decreased in both ovarian high-grade serous carcinoma 
and in various human ovarian cancer cell lines compared with normal ovary tissues 
and human ovarian surface epithelial cells (HOSE). Further functional analysis 
revealed that PDLIM2 is epigenetically repressed in ovarian cancer development and 
inhibition of PDLIM2 promoted ovarian cancer growth both in vivo and in vitro via 
NOS2-derived nitric oxide signaling, leading to recruitment of M2 type macrophages. 
These results suggest that PDLIM2 might be involved in ovarian cancer pathogenesis, 
which could serve as a promising therapeutic target for ovarian cancer patients. 
INTRODUCTION
Ovarian cancer occurs in 1 of 2500 post-menopausal 
females in the United States and has been considered the 
most lethal gynecologic malignancy, accounting for 5–6% 
of all cancer-related mortalities worldwide [1]. Patients 
with advanced ovarian cancer are mainly treated with 
surgical cytoreduction, followed by chemotherapy, with a 
clinical response rate of 60–70%. However, many patients 
ultimately succumb to relapse resistant to chemotherapy, 
yielding an overall 5-year 10-30% survival rate [2]. 
Therefore, it is imperative to develop novel therapeutic 
strategies treating advanced or recurrent ovarian cancer. 
The role of inflammation in ovarian carcinogenesis 
was first proposed in the ‘incessant ovulation theory’ 
[3]. Rupture of the ovarian surface epithelium induces 
an inflammatory reaction causing cell damage and 
proliferation, enhancing potential aberrant DNA 
repair, inactivating tumor-suppressor genes, leading to 
subsequent mutagenesis. Chronic diseases of the female 
reproductive tract (including endometriosis, polycystic 
ovary syndrome and pelvic inflammatory disease) are 
associated with inflammation, and are purported epithelial 
invasive ovarian cancer (EOC) risk factors [4]. Recently, 
both mouse and human studies suggest nuclear factor-
κB (NF-κB) transcription factor plays a causative role 
in inflammation, and subsequently, the pathogeneses of 
ovarian cancer [5]. Deregulation of NF-κB activity may 
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influence the outcome in women receiving standard 
therapy for advanced ovarian cancer. Moreover, as a key 
regulator of NF-κB signaling, inhibitors of IkB kinases 
(IKK) were recently demonstrated to play a critical role in 
both invasive and metastastic ovarian cancer processes [6]. 
These observations demonstrate NF-κB signaling is vital 
in ovarian cancer oncogenesis and progression. NF-κB 
activity is tightly regulated during physiologic conditions. 
Typically, NF-κB is rapidly activated transiently in 
response to different stimuli. One essential mechanism 
for the swift termination of the NF-κB response involves 
nuclear degradation of its prototypic member p65, a 
process predominantly controlled by PDZ-LIM domain-
containing Protein 2 (PDLIM2) [7]. PDLIM2 is the most 
recently discovered PDZ-LIM domain-containing protein. 
The COOH-terminal LIM domain of PDLIM2 is essential 
for promoting ubiquitination of nuclear p65, whereas 
its NH2-terminal PDZ domain participates in shuttling 
nuclear p65 along the nuclear framework into discrete 
intranuclear compartments for proteasome-mediated 
degradation. Accordingly, PDLIM2 knockout mice are 
more sensitive to lipopolysaccharide(LPS)-induced shock 
due to enhanced NF-κB/p65 activation and augmented 
inflammatory cytokines production [8]. 
Currently, the specific molecular mechanisms 
underlying ovarian cancer pathogenesis remains unclear. 
Herein, we demonstrate PDLIM2 is decreased in both 
ovarian high-grade serous carcinoma and in various 
human ovarian cancer cell lines compared to normal 
ovarian tissues and human ovarian surface epithelial cells 
(HOSE). Further functional analysis revealed PDLIM2 is 
epigenetically repressed in ovarian cancer development. 
Inhibition of PDLIM2 promoted ovarian cancer growth 
both in vivo and in vitro via NOS2-derived nitric oxide 
signaling, leading to M2 type macrophages recruitment. 
These results suggest an important role of PDLIM2 in 
ovarian cancer pathogenesis, which might be a promising 
therapeutic target in the clinical treatment of ovarian 
cancer.
RESULTS
PDLIM2 expression is repressed in ovarian cancer 
and is associated with patient prognosis
Given the critical role of NF-κB in ovarian 
cancer pathogenesis and the involvement of PDLIM2 in 
terminating NF-κB activation, we hypothesized PDLIM2 
is involved in the ovarian cancer pathogenesis. We 
determined PDLIM2 levels in normal ovary, fallopian 
tube, and high grade serous ovarian carcinoma (HGSC) 
specimens. PDLIM2 protein expression is significantly 
decreased in HGSC specimens (Figure 1A). Further 
RT-PCR analysis revealed PDLIM2 mRNA level is 
significantly decreased in ovarian cancer tissues compared 
to normal ovary and fallopian tube tissues (Figure 1B). 
We next investigated previously published microarray data 
regarding PDLIM2 expression in the Oncomine database. 
PDLIM2 mRNA levels were decreased in ovarian cancer 
tissues compared to normal tissue in the Yoshihara and 
Figure 1: Repression of PDLIM2 is associated with ovarian cancer prognosis. A. immunolocalization of PDLIM2 showing 
high PDLIM2 protein expression in normal ovarian and fallopian tube tissue samples and low PDLIM2 expression in high-grade serous 
ovarian carcinoma samples. HGSC: high-grade serous ovarian carcinoma. B. scatter plot showing the distribution of relative PDLIM2 
expression intensity in the normal ovarian tissues, normal fallopian tube tissues, and high-grade serous ovarian carcinoma tissues. C. box 
plot showing significantly lower PDLIM2 protein expression in ovarian tumor samples compared with normal ovarian tissues in both 
Yoshihara dataset and Hendrix dataset. D. Kaplan–Meier analysis of the Australian Ovarian Cancer Study(AOCS) patients with ovarian 
carcinoma showing a significant correlation between PDLIM2 protein expression and progression-free survival, overall survival, and post-
progression survival. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Hendrix datasets (P=1.22E-4 and P=1.87E-7, respectively) 
(Figure 1C). We next performed quantitative real-time 
PCR and immunoblotting to respectively determine 
PDLIM2 mRNA and protein levels in ovarian cancer 
cells and control HOSE cells. Both PDLIM2 mRNA 
levels and protein levels are significantly decreased in all 
ovarian cancer cell lines compared to control (Figure 2A 
and 2B). Survival analysis revealed PDLIM2 repression 
was associated with decreased progression-free survival, 
overall survival, and post-progression survival (Figure 
1D). These data suggest PDLIM2 protein expression is 
repressed in ovarian cancer, and its decreased expression is 
associated with poor prognosis in ovarian cancer patients.
PDLIM2 expression attenuates ovarian cancer 
growth
To further investigate the effect of PDLIM2 
expression in ovarian cancer, we performed a colony 
formation assay, employing OVCAR-3 and Caov-3 
cells expressing PDLIM2 versus empty vector. Both 
OVCAR-3 cells (Figure 3A) and Caov-3 cells (Figure 
3B) expressing PDLIM2 formed markedly fewer and 
smaller colonies compared to control, suggesting PDLIM2 
suppresses ovarian cancer growth in vitro. To validate 
these observations in vivo, we separately incubated the 
control vector and PDLIM2-expressing ovarian cancer 
cells subcutaneously in nude mice. As shown in Figure 
3C and 3D, both control vector and PDLIM2-expressing 
cells of OVCAR-3 and Caov-3 cells developed tumors 
subcutaneously in nude mice. However, PDLIM2-
expressing ovarian cancer cells were significantly smaller 
than those formed by the vector-expressing cell lines. 
Taken together, these data support PDLIM2-mediated 
suppression of ovarian cancer cell tumorigenicity. 
PDLIM2 repression in ovarian cancer involves 
DNA methylation
Next, we investigated the underlying mechanism of 
PDLIM2 repression in ovarian cancer, and asssessed the 
potential role of DNA methylation, a major mechanism 
Figure 2: Repression of PDLIM2 expression in ovarian cancer cell lines. A. Protein expressions of PDLIM2 in the indicated 
ovarian cancer cell lines and human ovarian surface epithelial cells(HOSE). β-actin was used as a loading control. B. The relative levels of 
PDLIM2 mRNAs in the indicated ovarian cancer cells and HOSE cells were analyzed by real-time PCR using GAPDH mRNA as a control 
and represented as percentile of that in HOSE cells (set as 100). The data presented are the mean±S.D. (error bars) .
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responsible for tumor suppressor gene suppression in 
malignant cells. We first analyzed the expression levels 
of three DNA methyltransferases responsible for DNA 
methylation (DNMT1, DNMT3a, and DNMT3b). All 
three enzymes were significantly increased in each ovarian 
cancer cell line compared to nontumorigenic HOSE cells 
(albeit to different degrees Figure 4A). To further establish 
a correlation between DNA methyltransferase and 
PDLIM2 expression, we determined the effect of 5-aza-
dC, a highly specific DNA methyltransferase inhibitor, 
upon cancer cell PDLIM2 expression. 5-aza-dC treatment 
restored PDLIM2 expression in all studied ovarian cancer 
cell lines (Figure 4B). These data suggest PDLIM2 
repression in ovarian cancer involves DNA methylation. 
Interestingly, 5-aza-dC treatment also resulted 
in growth inhibition of OVCAR-3 and Caov-3 ovarian 
cancer cells (Figure 4C and 4D). To determine whether the 
PDLIM2 promoter is methylated in ovarian cancer cells, 
and whether 5-aza-dC–mediated restoration of PDLIM2 
expression involves inhibition of PDLIM2 promoter 
methylation, we performed bisulfite genomic DNA 
sequencing. The PDLIM2 promoter was hypermethylated 
in ovarian cancer cell lines compared to HOSE cells 
(Figure 4E). 5-aza-dC administration significantly reduced 
methylation of the PDLIM2 promoter. Together, these data 
suggest promoter methylation is an important modulating 
factor in the expression of PDLIM2 in ovarian cancer.
PDLIM2 inhibition increases endogenous NO 
level
We next investigated consequential downstream 
molecular events of PDLIM2 repression in ovarian 
cancer. We first compared the NO production capacity of 
PDLIM2-repressed OVCAR-3 and Caov-3 ovarian cancer 
cells by measuring nitrite (NO2-, a stable byproduct of NO) 
in culture medium. Both siPDLIM2-treated OVCAR-3 
and Caov-3 ovarian cancer cells produced significantly 
more NO than control (Figure 5A), suggesting PDLIM2 
repression may increase NO synthesis. To investigate the 
function of endogenous NO in ovarian cancer cells, we 
Figure 3: Suppression of tumorigenicities of ovarian cancer cells by PDLIM2. A. colony formation analysis of human 
OVCAR-3 ovarian cancer cells transfected with PDLIM2 compared with control. B. colony formation analysis of human Caov-3 ovarian 
cancer cells transfected with PDLIM2 compared with control. C. growth suppression of OVCAR-3 ovarian cancer cancer cells by PDLIM2. 
D. growth suppression of Caov-3 ovarian cancer cancer cells by PDLIM2. The data presented are the mean±S.D. (error bars) . *, P < 0.05; 
**, P < 0.01; ***, P < 0.001.
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transfected OVCAR-3 and Caov-3 ovarian cancer cells 
with E. coli FlavoHb, a potent NO-consuming enzyme 
that converts NO to nitrate (NO3-) (Figure 5B and 5C). 
FlavoHb reduced NO synthesis in PDLIM2-repressed 
ovarian cancer cells (Figure 5D), and inhibited both 
OVCAR-3 and Caov-3 cellular growth (Figure 5E and 
5F). Taken together, these data suggest PDLIM2 inhibition 
increases endogenous NO levels, with increased resultant 
ovarian cancer cell growth.
NOS2 expression is increased in PDLIM2-
repressed ovarian cancer cells
Although we demonstrated FlavoHb blocked NO 
availability and decreased ovarian cancer cell growth, 
the source of PDLIM2-repressed cell-derived NO 
remains unclear. There are three isoforms of nitric oxide 
synthases: NOS1, NOS2 (iNOS), and NOS3 (eNOS). 
Figure 4: DNA methylation-mediated repression of PDLIM2 in ovarian cancer cells. A. Relative mRNA levels of DNMT1, 
DNMT3a, and DNMT3b in human ovarian cancer cells and HOSE cells by RT-PCR analysis. B. 5-aza-dC-mediated recovery of PDLIM2 
expression in human ovarian cancer cells and HOSE cells by RT-PCR analysis. PDLIM2 mRNA levels in the 5-aza-dC- or mock-treated 
cells were also analyzed by RT-PCR. The PDLIM2 inductions by 5-aza-dC are represented as percentile of that in mock-treated HOSE cells. 
C. growth curve of OVCAR-3 ovarian cancer cells treated by 5-aza-dC. D. growth curve of Caov-3 ovarian cancer cells treated by 5-aza-
dC. E. methylation of the PDLIM2 promoter in ovarian cancer cells. The indicated cell lines were treated with 5 μM 5-aza-dC or vehicle 
for 5 days, followed by the bisulfite genomic DNA sequencing. Each circle represents a CpG site; open circles represent unmethylated 
CpG dinucleotides, and filled circles represent methylated CpG sites. The ratios of the filled area in circles represent percentiles of the 
methylation in the CpG sites. The position of each CpG nucleotide relative to the PDLIM2 transcription initiation site (+1) is indicated at 
the top. The data presented are the mean±S.D. (error bars) 
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We determined the mRNA and expression levels of these 
three NOS isoforms to identify which is responsible for 
increased NO synthesis in PDLIM2-repressed ovarian 
cancer cells. Via RT-PCR analysis, both OVCAR-3 and 
Caov-3 ovarian cancer cells exhibit elevated NOS2 mRNA 
levels after siPDLIM2 treatment (Figure 6A), consistent 
with the finding confirmed by immunoblotting (Figure 
6B). No significant change was observed in the NOS1 and 
NOS3 mRNA levels (Figure 6A). Immunohistochemistry 
analysis revealed NOS2 expression is significantly 
increased in PDLIM2-repressed ovarian cancer specimens 
(Figure 6C). Correlation analysis demonstrated tumor 
expression of NOS2 is negatively correlated with PDLIM2 
levels (r2=0.2082; P=0.0328) in ovarian cancer specimens, 
suggesting a functional link between the two factors 
(Figure 6D). Additionally, survival analysis revealed 
increased expression of NOS2 was associated with 
decreased progression-free survival and overall survival 
(Figure 6E). These data demonstrate NOS2 may be an 
important mediator in PDLIM2-repression-induced NO 
synthesis in ovarian cancer. 
Inhibition of NO synthesis attenuates ovarian 
cancer growth in vitro and in vivo
To further evaluate the functional import of NO in 
ovarian cancer growth, we assessed OVCAR-3 and Caov-
3 cells in vitro during conditions of impaired NOS2/NO 
signaling. Both NOS2 inhibitor 1400W (Figure 7A) and 
PTIO (Figure 7B) significantly reduced the growth rate 
of siPDLIM2-treated ovarian cancer cells compared with 
control. To directly determine the importance of NOS2 
in siPDLIM2-treated ovarian cell growth, we employed 
NOS2-targeting siRNA for functional validation. Impaired 
NOS2 expression reduced siPDLIM2-treated OVCAR-3 
and Caov-3 cell growth in vitro, compared to control 
(Figure 7C and 7D). To examine the role of NO synthesis 
in ovarian cancer growth in vivo, we treated PDLIM-
2-repressed OVCAR-3 and Caov-3 cancer cells with 
NOS2 siRNA or control. NOS2-siRNA decreased both 
OVCAR-3 (Figure 8A) and Caov-3 (Figure 8B) cancer 
cell growth in vivo, in statistically significant fashion 
(Figure 8C and 8D). These data support the implications 
of NOS2-induced NO synthesis upon ovarian cancer cell 
growth.
Figure 5: PDLIM2 repression triggers increased NO synthesis in ovarian cancer. A. Nitrite (NO2-) was quantified in the 
media of different cells. B. immuobloting of flag-tagged FlavoHb expression in OVCAR-3 ovarian cancer cells. C. immuobloting of 
Flag-tagged FlavoHb expression in Caov-3 ovarian cancer cells. D. FlavoHb expression decreased the total nitrite measured in media in 
PDLIM2-repressed ovarian cancer cells. E. FlavoHb impairs growth of PDLIM2-repressed OVCAR-3 cancer cells. F. FlavoHb impairs 
growth of PDLIM2-repressed Caov-3 cancer cells. The data presented are the mean±S.D. (error bars) . *, P < 0.05; **, P < 0.01; ***, P < 
0.001.
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PDLIM2 repression recruits M2 type tumor-
associated macrophage infiltration in ovarian 
cancer, reversed by NOS2 inhibition 
To characterize whether PDLIM2 suppression 
alters the tumor microenvironment, we analyzed the 
percentage of M2 type tumor macrophage cell infiltration 
in an ovarian cancer xenograft by immunohistochemistry. 
Analyses of CD163-immunostained tumor sections 
revealed increased M2 type tumor-associated macrophage 
infiltration in siPDLIM2-transfected OVCAR-3 (Figure 
9A) and Caov-3 (Figure 9B) ovarian cancer cell specimens 
compared to control. However, siNOS2 treatment 
Figure 6: Enhanced expression of NOS2 in PDLIM2-repressed ovarian cancer cells. A. detection of NOS1, NOS2, and 
NOS3 expression in PDLIM2-repressed OVCAR-3 and Caov-3 ovarian cancer cells and control by RT-PCR. B. detection of NOS1, 
NOS2, and NOS3 expression in PDLIM2-repressed OVCAR-3 and Caov-3 ovarian cancer cells and control by immunoblotting. C. NOS2 
immunostaining of paraffin-embedded PDLIM2-high and PDLIM2-low ovarian cancer specimens. D. correlation of NOS2 and PDLIM2 
expression in ovarian cancer specimens. E. Kaplan–Meier analysis of the Australian Ovarian Cancer Study(AOCS) patients with ovarian 
carcinoma showing a significant correlation between NOS2 protein expression and progression-free survival and overall survival.
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significantly decreased the percentage of CD163-positive 
cells in both siPDLIM2-transfected OVCAR-3 and Caov-
3 ovarian cancer cell xenografts. These data demonstrate 
PDLIM2 suppression increases M2 type tumor-associated 
macrophage recruitment in the ovarian cancer tumor 
microenvironment, attenuated by NOS2 inhibition.
DISCUSSION
The lack of efficient early detection strategies and 
limited treatments options contribute to high mortality 
in advanced stage ovarian cancer patients [2]. Therefore, 
comprehension of the underlying molecular mechanisms 
of ovarian cancer pathogenesis is of utmost importance 
with potential therapeutic value. In the current study, 
we demonstrate PDLIM2 expression was inhibited in 
both ovarian high-grade serous carcinoma and in several 
human ovarian cancer cell lines compared to normal 
ovarian tissues and human ovarian surface epithelial 
cells (HOSE). Functional analysis revealed PDLIM2 is 
epigenetically repressed in ovarian cancer development. 
PDLIM2 inhibition promoted ovarian cancer growth 
both in vivo and in vitro via NOS2-derived nitric oxide 
signaling, which increased M2 type macrophage 
recruitment. Together, these results suggest PDLIM2 has 
an important role in ovarian cancer pathogenesis, and 
may be a promising therapeutic target in the treatment of 
Figure 7: Impaired growth of PDLIM2-repressed ovarian cancer cells under NOS2/NO inhibition in vitro. A. growth of 
PDLIM2-repressed OVCAR-3 cells and control after treatment with 1400W. B. growth of PDLIM2-repressed OVCAR-3 cells and control 
after treatment with PITO. C. growth of PDLIM2-repressed OVCAR-3 cells and control after treatment with NOS2 siRNA. D. grow curve 
of PDLIM2-repressed OVCAR-3 cells and control after treatment with NOS2 siRNA. The data presented are the mean±S.D. (error bars) . 
*, P < 0.05; **, P < 0.01; ***, P < 0.001.
Oncotarget1416www.impactjournals.com/oncotarget
Figure 9: NOS2 inhibition reduces M2 type tumor-associated macrophage infiltration in PDLIM2-low ovarian cancer. 
Representative micro-photographs (left) and quantifications (right) of CD163-positive macrophage content in OVCAR-3 A. and Caov-3 B. 
tumor xenografts, respectively. The data presented are the mean±S.D. (error bars) . *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure 8: NOS2 inhibition reduces PDLIM2-repressed ovarian cancer growth in vivo. A. growth curves of PDLIM2-
repressed OVCAR-3 cells treated with siNOS2 or control in vivo. B. growth curves of PDLIM2-repressed Caov-3 cells treated with siNOS2 
or control in vivo. C. length of time to reach 15 mm3 tumor size of PDLIM2-repressed OVCAR-3 cells treated with siNOS2 or control. D. 
length of time to reach 15 mm3 tumor size of PDLIM2-repressed Caov-3 cells treated with siNOS2 or control. The data presented are the 
mean±S.D. (error bars) . *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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ovarian cancer.
PDLIM2 has a PDZ domain (that binds with the 
actin cy toskeleton via α-actinin) and a LIM do main 
(that has potential to associate with different protein 
partners). PDLIM2 shuttles between the cytoskeleton 
and nucleus, and participates in cytoskeletal signaling, 
cellular polarization, and cellular migration[9]. Recent 
studies has demonstrated PDLIM2 specifically targets 
nuclear p65 for polyubiquitination-mediated proteasomal 
degradation, terminating NF-KB activation [7]. It has 
been suggested the C-terminal LIM domain of PDLIM2 
is required for promoting ubiquitination of nuclear p65, 
while its N-terminal PDZ domain shuttles nuclear p65 
along the nuclear framework into discrete intranuclear 
compartments for proteasome-mediated degradation [8]. 
Correspondingly, PDLIM2 knock-out mice are more 
sensitive to lipopolysaccharide-induced shock due to 
enhanced p65 activation and subsequently augmented 
production of inflammatory cytokines [8]. Apart from its 
involvment in inflammation, its role as a tumor suppressor 
has also been highlighted. PDLIM2 is repressed in a 
variety of tumors, including breast [7] and colon cancer 
[10]. The molecular mechanisms underlying its decreased 
expression involve promoter methylation. Heretofore, 
whether PDLIM2 is similarly repressed in ovarian cancer 
has not been investigated. Our current study demonstrated 
PDLIM2 is epigenetically repressed in ovarian cancer, 
and restoration of PDLIM2 significantly impaired ovarian 
cancer growth, suggesting an important role of PDLIM2 
in ovarian cancer development. 
Nitric oxide (NO) is an important regulator of 
a variety of physiological functions, but continuous 
exposure to moderate-to-high concentrations of NO may 
lead to pathological processes such as inflammation, 
apoptosis, and tumorigenesis [11]. iNOS–NO signaling has 
been reported to be closely correlated with tumorigenesis, 
but its contribution in ovarian cancer pathogenesis remain 
unknown. Previous studies have reported homeoprotein 
DLX4 regulated inducible nitric oxide synthase-mediated 
angiogenesis in ovarian cancer [12]. Moreover, Caneba et 
al. demonstrated NO positively orchestrated the Warburg 
effect (increased glycolysis with reduced mitochondrial 
activity during aerobic conditions). NO promotes 
tumor growth and inhibits mitochondrial respiration in 
OVCA cells, metabolically shifting these cells towards 
glycolysis to maintain ATP production. Additionally, NO 
increases TCA cycle flux and glutaminolysis, suggesting 
NO decreases ROS levels by increasing NADPH and 
glutathione levels [13]. Our study demonstrated NOS2 
expression was increased in PDLIM2-repressed ovarian 
cancer cells , increasing intracellular NO synthesis in 
ovarian cancer cells. Via NO synthesis inhibition, we 
demonstrated PDLIM2-deficient ovarian cancer cells grow 
in a NO-dependent manner. Taken together, our results 
support the vital role NO signaling plays in PDLIM2-
repressed ovarian cancer cell growth.
Previous investigations have demonstrated 
macrophage infiltration in the tumor microenvironment 
favors tumor growth, angiogenesis, inflammation, 
metastasis/invasion, and immunosuppression through 
production of various factors promoting tumor 
progression. These factors serve as the interface 
between cancer cells and monocytes/macrophages under 
inflammatory stimuli in vitro and in vivo. Macrophages 
supporting aggressively malignant tumors are mostly the 
M2 type [14]. The number of M2 type tumor-associated 
macrophages is correlated with prognosis in different 
cancer types, including ovarian cancer [15]. Our study 
demonstrated the percentage of M2 type tumor-associated 
macrophages is significantly increased in PDLIM2-
deficient ovarian cancer specimens of nude mice model 
compared to control, suggesting the likely involvement of 
M2 type tumor-associated macrophages with PDLIM2-
repressed ovarian cancer cell growth. 
Taken together, our data demonstrated PDLIM2 
is repressed in ovarian cancer cells compared to 
normal tissue. Functional analysis revealed PDLIM2 is 
epigenetically repressed by DNA methylation in ovarian 
cancer, which is conducive to cellular growth both in 
vivo and in vitro via NOS2-derived nitric oxide signaling. 
M2 type macrophages recruitment was increased in 
the PDLIM2-repressed ovarian cancer tissue tumor 
microenvironment. Our results support an important role 
of PDLIM2 in ovarian cancer pathogenesis, which might 
be a promising therapeutic target in the treatment of 
ovarian cancer.
MATERIALS AND METHODS
Cell line, expression vectors, and reagents
The human ovarian cancer cell lines OVCAR-3, 
Caov-3, SKOV-3, were obtained from the American Type 
Culture Collection (ATCC). COV-504 and A2780 were 
obtained from the European Collection of Cell Cultures 
(ECACC). All cell lines were cultured per standard 
protocols. Human ovarian epithelial (HOSE) cells were 
isolated as previously described [16]. Plasmids encoding 
full-length human PDLIM2 were purchased from Gene 
Copoeia (Guangzhou, China). siRNA oligonucleotides 
with specificity for PDLIM2 and nontargeting control 
siRNA containing a scrambled sequence were from 
GenePharma. Nucleoside analogue 5-aza-2’-deoxycytidine 
(5-aza-dC), 1400W (N-{[3-(aminomethyl)phenyl]
methyl}-ethanimidamide, an irreversible NOS2 inhibitor); 
PTIO (2-phenyl-4,4,5,5-tetramethylimidazoline-1-
oxyl 3-oxide, a NO-scavenger), and crystal violet were 
purchased from Sigma-Aldrich. 
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Immunohistochemistry
Paraffin-embedded normal ovary, fallopian tube, and 
ovarian cancer specimens were obtained from 43 patients, 
who had undergone surgical resection from 2009 to 2010. 
Immunohistochemistry was performed utilizing primary 
antibodies, including mouse anti-PDLIM2 (diluted 1:200; 
abcam), rabbit anti-NOS2 (diluted 1:200; Santa Cruz 
Biotechnology), and rabbit anti-CD163 (diluted 1:200; 
Santa Cruz Biotechnology) as previously described 
(12). 10 random images per section were captured, and 
immunohistochemical staining positivity was determined 
by calculating the percentage of positive cells and 
immunostain intensity via Image-Pro Plus version 6.0 
(Media Cybernetics, Baltimore, MD). Staining intensities 
ranged 0 to 10. The mean value of staining intensity of 10 
captured images was considered each specimen’s staining 
score. All slides were evaluated by two independent 
pathologists in a double-blinded manner. Any discrepancy 
between the two evaluators was resolved by re-evaluation 
and open deliberation until agreement was reached.
Real-time PCR analysis 
Total RNA was obtained with TRIzol reagent. 
cDNA was generated with SuperScript II reverse 
transcriptase (Invitrogen). Real-time PCR assays were 
conducted as previously described. Primer pairs were 
PDLIM2 (forward 5’-GCCCATCATGGTGACTAAGG, 
reverse 5’-ATGGCCACGATTATGTCTCC); GAPDH 
(forward 5’-CGCTCTCTGCTCCTCCTGTT, reverse 
5’-CCATGGTGTCTGAGCGATGT); DNMT1 
(forward 5’-GGTTCTTCCTCCTGGAGAATGTC, 
reverse 5’-GGGCCACGCCGTACTG); DNMT3a 
(forward 5’-GCCTCAATGTTACCCTGGAA; reverse 
5’-CAGCAGATGGTGCAGTAGGA); and DNMT3b 
(forward 5’-CCCATTCGAGTCCTGTCATT, reverse 
5′-GGTTCCAACAGCAATGGACT).
Data set and survival analysis
The Oncomine database provides publicly available 
data sets concerning cancer gene expression. The 
Oncomine database was searched to further compare the 
expression levels of PDLIM2 and NOS2 in normal tissues 
and ovarian carcinomas. Kaplan Meier survival analysis 
data of ovarian cancer patients from the Australian 
Ovarian Cancer Study (AOCS) was collected [17].
Immunoblot
For immunoblotting, whole cell lysates were 
prepared as previously described [18]. Proteins from 
conditioned medium samples were precipitated by mixing 
1 ml sample with 5 ml methanol, followed by 1 hour of 
incubation at −80 °C. Samples were pelleted, dried, and 
subjected to further immunoblotting. All signals were 
quantified by QuantityOne software (Bio-Rad), and 
defined as the ratio of target protein to β-actin. 
Cell growth assays
Cells were seeded into 12-well plates at a density of 
5,000 cells per well. Cells received 5-aza-dC (5 μmol/L) 
or vehicle treatment. The drug-containing medium was 
replenished each day. Cell density was determined by 
replacing the medium with 2 μmol/L of calcein AM in 1× 
dissociation solution (Trevigen) at indicated time points. 
After 1 hour incubation, diesterase activity (in relative 
fluorescence units) was measured via Tecan Infinite 200 
Microplate Reader (excitation wavelength 485 nm and 
emission wavelength 520 nm).
Colony formation assay
100 cells were counted and seeded in triplicate in 
a 6-well plate, and cultured continuously for 14 days. All 
subsequent clones were stained with crystal violet and 
counted via light microscopy. Any clusters exceeding 50 
cells was considered a clone, and clonogenic formation 
rate was calculated.
Bisulfite genomic DNA sequencing 
Genomic DNA from 5-aza-dC–treated or mock-
treated cells was isolated via PureLink Genomic DNA 
Purification Kit (Invitrogen) per manufacturer’s protocol. 
Subsequently, genomic DNA aliquots were treated 
with sodium bisulfite via EZ DNA Methylation-Gold 
Kit (Zymo Research), followed by PCR to amplify the 
PDLIM2 promoter by Hot-Start Taq enzyme (Qiagen). 
Primers were designed to recognize the bisulfite-modified 
regions (−1084 to −800) of the PDLIM2 promoter 
(forward 5′-AGAGGAGTTTATATATATTTAGG, reverse 
5′-TACCTAACAACCCTCTCTCC). The PCR products 
were then directly employed for DNA sequencing or 
subcloned into the SmaI restriction site of pEGFP-N2 
(Clontech) for single colony sequencing to determine the 
methylation status of the CpG dinucleotides within the 
PDLIM2 promoter. 
Xenograft study
Xenograft experiments were conducted per national 
guidelines and approved by the Institutional Animal Care 
and Use Committee of Sichuan University (Chengdu, 
Sichuan, China), as done previously [19]. Briefly, 2×106 
cancer cells were subcutaneously injected in the right 
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flank of 5-7 week old severely combined immunodeficient 
(SCID) mice. Tumor growth was assessed over time 
by twice weekly physical examination and palpation. 
Mice were sacrificed 21 days after inoculation. Tumors 
were frozen in liquid nitrogen and stored at -75°C for 
subsequent analyses.
Nitrite Level Determination by 
4,5-Diaminofluorescein
To determine cellular nitrite production, 
conditioned supernatants or nitrite standards were 
added to 4,5-diaminofluorescein (DAF-2; Cayman 
Chemical). Samples were analyzed post-acidification and 
neutralization for fluorescence (measured with lex=488nm 
and lem=525 nm). All results were normalized to cellular 
protein content (measured by Bradford assay; Bio-Rad).
Statistical analysis
GraphPad Prism 5.0d for Mac (GraphPad Software) 
was utilized for all statistical analyses. Data was reported 
as mean±standard deviation. Student’s t test (two-
tailed) assessed the significance of differences between 
two groups. p values<0.05 and 0.01 were respectively 
considered statistically significant and highly statistically 
significant. Spearman correlation analyzed the potential 
correlation between two different experimental parameters 
(*, P < 0.05; **, P < 0.01).
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